articleThe LancetJan 1, 2012Closed access

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Seoul National University · National University College · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,720
total citations
FWCI
96.53
Percentile
100%
References
30
Citations per year

Authors

17

Topics & keywords

Keywords
  • Medicine
  • Capecitabine
  • Oxaliplatin
  • Gastrectomy
  • Cancer
  • Internal medicine
  • Clinical endpoint
  • Interim analysis
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.